FDA and NIH Take Actions to Reduce Reliance on Animal Testing with New Draft Guidance and Funding Announcement
March 20, 2026Policy & Regulation, Food and Drug Administration (FDA), Life Sciences, FDA Enforcement
On March 18, 2026, the Food and Drug Administration (FDA) issued draft guidance entitled “General Considerations for the Use of New Approach Methodologies in Drug Development.” The guidance is meant to provide drug developers with a validation framework and general recommendations for using new approach methodologies (NAMs) in drug development. The use of NAMs can improve predictive toxicology in humans and reduce reliance on animal testing.
Get the latest FDA and related regulatory developments critical to the life sciences industry delivered to your inbox.
